



27th October 2025

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001
Scrip Code: 500674

The Secretary
The National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra East,
Mumbai 400 050
Symbol: SANOFI

Sub: Outcome of Board Meeting of the Company held on Monday, 27th October 2025

Dear Sir / Madam,

We wish to inform you that the Board of Directors, at its meeting held today i.e., Monday, 27th October 2025, inter-alia considered and approved the following matter(s):

- Upon the recommendation of the Nomination and Remuneration Committee and subject to approval of the Shareholders and the Central Government, the Board of Directors have approved the appointment of Mr. Deepak Arora (DIN: 07495638) as an Additional Director of the Company with effect from 27th October, 2025 and as a Managing Director (Key Managerial Personnel) of the Company for a term of 3 (three) years effective from 27th October, 2025. The Board has also authorized Mr. Deepak Arora to determine the materiality of any event or information and to make disclosures to the Stock Exchanges, in addition to other authorized Key Managerial Personnels of the Company. A press release in this regard has also been enclosed as 'Annexure II'.
- With reference to our Intimation dated 16th July 2025, informing about the appointment of Mr. Rachid Ayari (DIN: 10408699) as the Interim Managing Director of the Company, in addition to his existing role as the Chief Financial Officer of the Company, for a term of 6 months from 21st July 2025 to 20th January 2026 or until a Permanent Managing Director is appointed, whichever is earlier, we wish to inform you that Mr. Rachid Ayari have stepped down from his position as Interim Managing Director of the Company with effect from close of 26th October 2025. However, Mr. Rachid Ayari would continue to serve the Company in his role as Whole-time Director and Chief Financial Officer of the Company. The Board of Directors have placed on record their immense appreciation for Mr. Rachid Ayari for his valuable contribution during his tenure as the Interim Managing Director with the Company. A copy of his letter is enclosed as 'Annexure-III'.



The information as required in terms of Regulation 30 read with Schedule III of the Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 is enclosed as 'Annexure-I'.

The meeting of Board of Directors commenced at 2:00 p.m. and concluded at 4.28 p.m.

Please take the above information on record.

Thanking you,

Yours faithfully
For **Sanofi India Limited**

Haresh Vala
Company Secretary and Compliance Officer
Membership No.: A18246

Encl: Annexure – I, II and III

Information as required under Regulation 30 read with Schedule III - Para A of Part A of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

1. Mr. Rachid Ayari (DIN: 10408699) stepping down as the Interim Managing Director of the Company:

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Mr. Rachid Ayari (DIN: 10408699) stepping down from his position as Interim Managing Director of the Company. However, Mr. Ayari would continue to serve the Company in his role as the Whole-time Director and Chief Financial Officer of the Company.
2.	Date of appointment / re-appointment / cessation (as applicable) & term of appointment;	Mr. Rachid Ayari would be stepping down from his position as Interim Managing Director of the Company with effect from close of 26 th October 2025.
3.	Brief profile (in case of appointment)	-
4.	Disclosure of relationships between directors (in case of appointment of a director).	-
5.	Names of listed entities in which the resigning Director holds directorships, indicating the category of directorship and membership of board committees, if any.	Not Applicable as Mr. Rachid Ayari continues to be the Whole-time Director and Chief Financial Officer of the Company.

2. Appointment of Mr. Deepak Arora (DIN: 07495638) as the Additional Director and Managing Director of the Company:

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment of Mr. Deepak Arora (DIN: 07495638) as the Additional Director and Managing Director (Key Managerial Personnel) of the Company, subject to the approval of the shareholders and Central Government.

<p>2.</p>	<p>Date of appointment / re-appointment / cessation (as applicable) & term of appointment;</p>	<p>Appointed as an Additional Director of the Company with effect from 27th October, 2025.</p> <p>Appointed as the Managing Director (Key Managerial Personnel) of the Company for a period of 3 (three) years with effect from 27th October, 2025.</p>
<p>3.</p>	<p>Brief profile (in case of appointment)</p>	<p>Mr. Deepak Arora is a pharma expert with 30+ years of insightful experience in leading sales & marketing teams, rolling out marketing strategies, developing brands and spearheading product management, eventually developing newer markets, acquiring business and generating substantial growth. He has extensive exposure of working in Pharmaceutical and Healthcare domains combined with hands-on knowledge of several pharmaceutical product portfolios, market dynamics and industry trends. Mr. Arora is a consistent achiever, recognized for completing pre-defined sales targets and other organizational objectives throughout the career, exploring challenging opportunities with established companies, to leverage acquired skill sets and deliver beneficial outcomes. He is a Business & People Leader with experience in new product development. Mr. Arora is familiar with and experienced in international markets (US, Europe, Japan, Africa, Middle East). He has hands-on experience in developing strategic plans and leading the marketing function.</p> <p>Mr. Deepak Arora is proficient in formulating and executing annual business plans for growth. He has been part of Area leadership teams across the organization he has worked. Mr. Arora has interest in Real World Evidence with Health Economics Outcome Research Experience with India and International. He has Work Experience- Local and Global matrix environment with high level of cross-functional coordination and alignment to deliver projects on timelines.</p>

<p>4.</p>	<p>Disclosure of relationships between directors (in case of appointment of a director).</p>	<p>Mr. Deepak Arora is not related to any of the Directors of the Company personally, financially or otherwise.</p>
<p>5.</p>	<p>Information pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and NSE Circular NSE/CML/2018/24 ('Circulars')</p>	<p>Mr. Deepak Arora is not debarred or disqualified from being appointed or continuing as director of any company by SEBI / Ministry of Corporate Affairs or any such authority as required under the Circulars. Signed disclosure is enclosed herewith.</p>

Press Release

India



Sanofi India Limited appoints new Managing Director

Mumbai, October 27, 2025. Sanofi India Limited (SIL) today announced that its Board of Directors, on the recommendation of the Nomination and Remuneration Committee, has appointed **Deepak Arora** as the Company's Managing Director with effect from October 27, 2025, subject to the approval of the shareholders and the Central Government.



In this role, Deepak will define and drive the strategic vision for India in alignment with Sanofi's global strategy. He will also spearhead strategic priorities to accelerate innovation and agility throughout the organization, while fostering operational excellence across all functions.

Furthermore, Deepak will champion the Company's Diversity, Equity, and Inclusion culture to bring our core values to life.

Deepak brings over 30 years of experience in the Pharmaceutical & Healthcare industry across North America, Europe, Middle East and Africa. He has held leadership positions in Commercial, Sales & Marketing, and General Management roles, acquiring businesses and generating sustainable growth within several multinational companies.

Aditya Narayan

Chairman of the Board, Sanofi India Limited

"On behalf of the Board of Directors, I am delighted to welcome Deepak Arora as the Managing Director. His extensive pharmaceutical experience across diverse geographies aligns perfectly with our endeavour to serve patients throughout India. We are confident that under his leadership, Sanofi will continue to thrive and innovate. We extend our wholehearted support and best wishes as he embarks on this significant journey."

Deepak holds a Bachelor's degree in Botany & Zoology from the University of Lucknow and is an MBA from the Indira Gandhi National Open University.

Sanofi in India

Present in India for nearly seven decades, Sanofi has earned the trust of customers and stakeholders for its commitment to promoting health. As Sanofi chases the miracles of science to improve people's lives, it continues to engage across the entire health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building.

Sanofi's India Charitable Access Program (InCAP) is the country's longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. Sanofi conducts clinical trials in India, so that the country can have quicker access to the latest from the company's global pipeline. Sanofi India's world-class manufacturing site in Goa produces for people in India and 60+ other countries. Sanofi has located one of its global talent hubs in Hyderabad, India, from where wide range of services are provided globally.

Recognized by the 'Top® Employers Institute' – a global authority that honours excellence in people practices since 2019, Sanofi's local entities include Sanofi India Limited (SIL - listed entity), and Sanofi Healthcare India Pvt. Ltd. (SHIPL).

For more information, visit: www.sanofi.com/en/in, [LinkedIn](#) and [Twitter](#).

Media Relations

Vinifer Gandhi | vinifer.gandhi@sanofi.com

Annexure III

To
Mr. Aditya Narayan
Chairman
Sanofi India Limited

Subject – Stepping down from the position of Interim Managing Director of the Company

Dear Chairman,

I am writing to inform you that, in accordance to my terms of appointment as "Interim Managing Director" of the Company, in addition to the existing role as the Chief Financial Officer of the Company, for a term of 6 months from 21st July 2025 to 20th January 2026 or until a Permanent Managing Director is appointed, whichever is earlier, I would like to step down from the position of "Interim Managing Director" of the Company with effect from close of 26th October, 2025. However, I would continue to serve the Company in my role as Whole-time Director and Chief Financial Officer of the Company.

I would like to take this opportunity to express my sincere gratitude to all Board Members for the invaluable support and collaboration I have received during my tenure as Interim Managing Director. I appreciate the trust placed in me and grateful for the experience and knowledge gained.

Thank you.

Regards,

Rachi Ayari



Mumbai

Date: 24th October 2025

To,
The Board of Directors
Sanofi India Limited
Sanofi House, C.T.S-117 B
L&T Business Park, Saki Vihar Road,
Powai, Mumbai, Maharashtra, India, 400072

Sub: Non-Debarment Confirmation

I, **Deepak Arora**, hereby confirm that I have not been debarred from being appointed or continue as a Director of the Company by the Ministry of Corporate Affairs (MCA), Securities Exchange Board of India (SEBI), or any other statutory authority.

I shall inform the Company immediately upon any change in the above declaration.

Yours faithfully,



Name: Deepak Arora
DIN: 07495638
Date: 27th October 2025
Place: Goa